Stocksigma LogoStocksigma Logo

Ind-Swift Laboratories Reports Nil Deviation and Full Preferential Issue Proceeds Utilization

Ind-Swift Laboratories confirmed zero deviation in utilizing proceeds from its 30th Aug'24 preferential issue of 2.60 crore convertible warrants

Ind-Swift Laboratories Reports Nil Deviation and Full Preferential Issue Proceeds Utilization

Ind-Swift Laboratories Ltd · Others (Uncategorized) · 30 Oct 2026, 2:14 am

Ind-Swift Laboratories Reports Nil Deviation and Full Preferential Issue Proceeds Utilization Ind-Swift Laboratories confirmed zero deviation in utilizing proceeds from its 30th Aug'24 preferential issue of 2.60 crore convertible warrants. Total realizable proceeds were revised to ₹255.61 crore (against the original issue size of ₹314.60 crore) as ₹58.99 crore became non-receivable following an allottee's failure to exercise conversion rights by 28th Feb'26. The company has fully deployed the received ₹255.61 crore across business expansion (₹113.54 crore), general corporate purposes (₹75.00 crore), working capital (₹39.60 crore), and subsidiary investments (₹27.47 crore) as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Ind-Swift Laboratories Ltd

All Ind-Swift Laboratories Ltd announcements